Aerie Pharmaceuticals Announces Pricing of Initial Public Offering
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.--(BUSINESS WIRE)--
Aerie Pharmaceuticals, Inc., announced today the pricing of its initial
public offering of 6,720,000 shares of its common stock at a public
offering price of $10.00 per share, before underwriting discounts. The
shares are scheduled to begin trading on the NASDAQ Global Market on
October 25, 2013 under the ticker symbol "AERI." In addition, Aerie has
granted the underwriters a 30-day option to purchase up to an additional
1,008,000 shares of common stock at the same price to cover
over-allotments, if any.
The offering is expected to close on October 30, 2013, subject to
customary closing conditions.
RBC Capital Markets and Stifel are serving as joint book-running
managers for the offering. Canaccord Genuity Inc. and Needham & Company
are serving as co-managers.
A registration statement relating to the securities being sold in this
offering was declared effective by the Securities and Exchange
Commission on October 24, 2013. This offering is being made only by
means of a prospectus. A copy of the prospectus can be obtained from RBC
Capital Markets, LLC, Attention: Equity Syndicate, Three World Financial
Center, 200 Vesey Street, 8th Floor, New York, New York 10281, or by
telephone at (877) 822-4089, or from Stifel, Nicolaus & Company,
Incorporated, One Montgomery Street, Suite 3700, San Francisco,
California 94104, or by telephone at (415) 364-2720.
This news release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About Aerie Pharmaceuticals
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused
on the discovery, development and commercialization of first-in-class
therapies for the treatment of patients with glaucoma and other diseases
of the eye.
Aerie's lead product candidate, AR-13324, is the first of a new
dual-action drug class that was discovered by Aerie scientists. AR-13324
is a once-daily eye drop designed to reduce intraocular pressure in
patients with glaucoma or ocular hypertension. Aerie's product candidate
PG324 is a fixed combination of dual-action AR-13324 with latanoprost
formulated in a single eye drop and is designed to lower intraocular
pressure by reducing fluid inflow while also opening both of the eye's
Aerie is located in Bedminster, New Jersey, Research Triangle Park,
North Carolina, and Newport Beach, California.
Richard Rubino, 908-470-4320
McClellan, Inc., on behalf of Aerie Pharmaceuticals
Source: Aerie Pharmaceuticals
News Provided by Acquire Media
Close window | Back to top